AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01750957
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally daily, 12 weeks
Trial: NCT01750957
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose A orally daily, 12 weeks
Trial: NCT01750957
Drug: RO4917523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B orally daily, 12 weeks
Trial: NCT01366196
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
Trial: NCT03023059
Drug: Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet
RxNorm normalized name: Carbidopa-Levodopa, 25 mg-100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description
Trial: NCT03056339
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m2 by vein on Days -5 to -3.
Trial: NCT03056339
Drug: AP1903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
Trial: NCT00650403
Drug: Paxil® 40 mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg, single dose fed
Trial: NCT01272635
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
Trial: NCT01272635
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Trial: NCT01272635
Drug: Placebo Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
Trial: NCT00891228
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Trial: NCT00891228
Drug: Nestorone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
Trial: NCT00891228
Drug: Nestorone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
Trial: NCT00891228
Drug: Nestorone®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
Trial: NCT02967510
Drug: Estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02967510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01848119
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01957202
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
Trial: NCT01279616
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg on day +3
Trial: NCT00124956
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03761784
Drug: S6G5T-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day topical cream
Trial: NCT03761784
Drug: S6G5T-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day topical cream
Trial: NCT01772719
Drug: Simvastatin and zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1. Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.~2. Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly.
Trial: NCT00307125
Drug: Placebo plus immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosing: Adult Dosing (Subjects \>18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject \<\\=18 years): 375 mg/m\^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).~Standard immunosuppression is site-specific.
Trial: NCT00029523
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01032850
Drug: Sorafenib & Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Trial: NCT02652234
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01633814
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal estradiol, delivery rate 100 µg day-1
Trial: NCT01633814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo patch.
Trial: NCT01520896
Drug: NKTR-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 25 mg
Trial: NCT02211144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01952288
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin 40 mg/day for 12 months
Trial: NCT01952288
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT01001572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule or tablet taken orally once daily
Trial: NCT02083666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT01765179
Drug: Oral testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
Trial: NCT02997371
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administration as initially intravenous injection followed by a intravenous infusion
Trial: NCT00419783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03267940
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEGPH20 will be administered as per the schedule specified in the respective arms.
Trial: NCT03267940
Drug: CIS
RxNorm normalized name: Pacis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CIS will be administered as per the schedule specified in the respective arms.
Trial: NCT04526197
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib was administered orally as a single dose as one 200-mg tablet with 240 mL of water (fasting).
Trial: NCT00621387
Drug: ofloxacin and roxithromycin
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
Trial: NCT02441062
Drug: 68Ga-DOTATOC PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
Trial: NCT03631563
Drug: Immunosuppressive Agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG-Fresenius versus ATG
Trial: NCT00135967
Drug: mycophenolate mofetil orally 1000 mg twice a day (BID)
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00135967
Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00541723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
Trial: NCT02905760
Drug: Placebo filling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
Trial: NCT02905760
Drug: Vascular filling
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
Trial: NCT01216384
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive according to the dose group matching number of placebo tablets
Trial: NCT00713726
Drug: FentanyL
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
Trial: NCT04328636
Drug: Nebulized Magnesium Sulfate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized magnesium sulfate (isotonic solution) 256 mg every 15 minutes
Trial: NCT04328636
Drug: Intravenous Magnesium Sulfate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium sulfate 200 mg/kg over 30 minutes, followed by a continuous infusion at a rate of 50 mg/kg/hour
Trial: NCT00914160
Drug: Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00914160
Drug: Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00914160
Drug: Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03566810
Drug: Test GXR
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 500 mg of test GXR tablet (Merck Nantong/China) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Trial: NCT03566810
Drug: Reference GXR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a single oral dose of 500 mg of reference GXR tablet (Merck Darmstadt/France) under fasting or fed conditions on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Trial: NCT03876119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm/group descriptions.
Trial: NCT03386487
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator will be administered by mouth daily for eight weeks.
Trial: NCT01947751
Drug: CVC maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
Trial: NCT01883544
Drug: ALXN1007
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02591199
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02591199
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002896
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002896
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01144949
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one placebo capsule orally, once daily, with food for up to 4 weeks
Trial: NCT01631903
Drug: telepristone acetate 12 mg
RxNorm normalized name: zinc acetate 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg, vaginal capsule, once daily for 4 months
Trial: NCT01631903
Drug: telepristone acetate 12 mg
RxNorm normalized name: zinc acetate 12 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg, vaginal capsule, once daily, for 3 months
Trial: NCT01631903
Drug: telepristone acetate 24 mg
RxNorm normalized name: calcium acetate 5.24 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg, vaginal capsule, once daily for 4 months
Trial: NCT00495469
Drug: GSK189075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
Trial: NCT00495469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Available as Placebo matching tablet to GSK189075
Trial: NCT02943655
Drug: mefenamic acid (ponstan forte)
RxNorm normalized name: Meclofenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral 500 mg mefenamic acid three times per day
Trial: NCT00868231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
Trial: NCT03079089
Drug: Sequential Packaging (SET)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
Trial: NCT03079089
Drug: Prevention of GVHD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)~* Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)
Trial: NCT03079089
Drug: Care supports
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the protocols of each center
Trial: NCT03079089
Drug: Lymphocyte injection of prophylactic donor (PDLI)
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin Injection [ATGAM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90~- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade\> II.
Trial: NCT02725957
Drug: Saline 0.9% IV
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT06021574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00632619
Drug: Stimulant medication therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
Trial: NCT00596830
Drug: CP-751,871 (Figitumumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
Trial: NCT01278693
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg,twice daily, 16 weeks.
Trial: NCT00215878
Drug: D-serine (~2g /day)
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine \~2g /day), in the second arm adjuvant treatment with placebo (\~2g /day)
Trial: NCT01847989
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
Trial: NCT01444846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 0 mg ebselen, twice daily, 4 days
Trial: NCT03547895
Drug: vitamin K (Phytomenadione) 10 mg+ furosemide and spironolactone (Lasilactone) 50 mg + milk thistle (Silymarin) 140 mg + Albumin infusion
RxNorm normalized name: Milk thistle
DrugBank: Milk thistle (DB14375)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: symptomatic therapy for liver support, control of ascites and bleeding tendency.
Trial: NCT00276809
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03318016
Drug: Cyclophosphamide 500 MG
RxNorm normalized name: cyclophosphamide 500 MG
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 500 mg/m2 on day 4 as a single IV dose along with hydration for a maximum of 6 doses
Trial: NCT03635333
Drug: Flavor
RxNorm normalized name: FLAVOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flavor of e-juice (tobacco, menthol, strawberry)
Trial: NCT04517552
Drug: [11C]-CS1P1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] CS1P1. Participants will then undergo a \[11C\] CS1P1 PET/CT scan.
Trial: NCT03318016
Drug: Cyclophosphamide 1000 MG
RxNorm normalized name: cyclophosphamide 1000 MG
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 1000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Trial: NCT03318016
Drug: Cyclophosphamide 2000 MG
RxNorm normalized name: cyclophosphamide 2000 MG
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 2000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Trial: NCT03318016
Drug: Cyclophosphamide 3000 MG
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 3000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Trial: NCT01548209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
Trial: NCT03318016
Drug: Cyclophosphamide 4000 MG
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enrolled subjects will receive 3 consecutive days of ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide 4000 mg/m2on day 4 as a single IV dose along with Mesna (in subjects receiving ≥1000mg/m2 Cy) and hydration for a maximum of 6 doses
Trial: NCT03083522
Drug: Ojeok-San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT03083522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Trial: NCT02082236
Drug: Treatment Arm A: Sufenta®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
Trial: NCT02082236
Drug: Treatment B: Sufentanil SSM 30 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single-dose SSM 30 mcg
Trial: NCT01447732
Drug: CEP-37250/KHK2804
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.~Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1.